Open AccessEffect of YM992, a Novel Antidepressant With Selective Serotonin Re-uptake Inhibitory and 5-HT2A Receptor Antagonistic Activity, on a Marble-Burying Behavior Test as an Obsessive-Compulsive Disorder Model
Author(s) -
Hiromi Takeuchi,
Shin-ichi Yatsugi,
Tokio Yamaguchi
Publication year - 2002
Publication title -
japanese journal of pharmacology/japanese journal of pharmacology
Language(s) - English
Resource type - Journals
eISSN - 1347-3506
pISSN - 0021-5198
DOI - 10.1254/jjp.90.197
Subject(s) - citalopram , serotonin , pharmacology , fluoxetine , antidepressant , 5 ht receptor , inhibitory postsynaptic potential , behavioural despair test , chemistry , serotonin transporter , psychology , obsessive compulsive , serotonergic , receptor , medicine , psychiatry , neuroscience , biochemistry , hippocampus
YM992 ((S)-2-[[(7-fluoroindan-4-yl)oxy]methyl]morpholine) monohydrochloride is a novel antidepressant with selective serotonin (5-hydroxytryptamine, 5-HT) re-uptake inhibition and 5-HT(2A) receptor antagonistic activity. The effects of YM992 and two selective 5-HT re-uptake inhibitors (SSRIs) were studied in a marble-burying behavior test as a model of an obsessive-compulsive disorder (OCD) in mice at doses of 5, 10 and 15 mg/kg, i.p. YM992 and fluoxetine significantly inhibited marble-burying behavior at a dose of 15 mg/kg (i.p.) without affecting spontaneous locomotor activities. Citalopram also significantly inhibited the behavior at doses of 5, 10 and 15 mg/kg (i.p.) without affecting spontaneous locomotor activities. These results suggest that YM992, as well as SSRIs, may exhibit anti-OCD activity in addition to an antidepressive effect in clinical use.